NUWIQ®️ Dosing Options - Official Patient Site

NUWIQ Convenience and Flexible Dosing

NUWIQ is available in a wide range of dosage strength vials to accommodate individual dosing needs. Among currently approved FVIII products, only NUWIQ offers the lowest 2.5 ml diluent volume across all strengths.

Dosing Flexibility with NUWIQ

Available in 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU, 2500 IU, 3000 IU, and 4000 IU vials
Larger single-dose vials of 2500, 3000 and 4000 IU offer greater flexibility and convenience for patients requiring larger volumes of FVIII.
A patient who requires 3000 IU can use one 3000 IU vial instead of having to use a 2000 IU vial and a 1000 IU vial.
All NUWIQ vial sizes are reconstituted with an easy-to-use 2.5 ml syringe, pre-filled with water for injection
Each NUWIQ box comes with a vial adapter, butterfly needle, and alcohol swabs in addition to the NUWIQ vial and pre-filled syringe.

Storing NUWIQ

Keep NUWIQ in its original box in the refrigerator to protect it from exposure to light
- You can store NUWIQ in the refrigerator for up to 24 months at 36-46°F (2-8°C)
- NUWIQ can be kept at room temperature (up to 77°F [25°C]) for a single period not exceeding 3 months
- After being stored at room temperature, NUWIQ must not be put back into the refrigerator

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Use

NUWIQ^® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ^® is not indicated for the treatment of von Willebrand Disease.

Contraindications

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Adverse Reactions

The most frequently occurring adverse reactions (>5%) in clinical trials were upper respiratory tract infection, headache, fever, cough, lower respiratory tract infection, rhinitis, chills, abdominal pain, arthralgia, anemia, and pharyngitis.

Please See NUWIQ full Prescribing Information. Instructions For Use